Table 3.

Summary of Lymphocyte Apoptosis Defects in Nine Patients With ALPS

Patient No.Apoptosis Defect (% cell loss)3-150
Anti-CD3Anti-Fas
1 13 12 
2 26 35 
3 14 8 
4 37 17 
5 33 25 
6 8 21 
17 9 18 
20 ND 21 
143-151 27 60 
Normal controls (n = 3) 51 ± 1 87 ± 0.5 
Patient No.Apoptosis Defect (% cell loss)3-150
Anti-CD3Anti-Fas
1 13 12 
2 26 35 
3 14 8 
4 37 17 
5 33 25 
6 8 21 
17 9 18 
20 ND 21 
143-151 27 60 
Normal controls (n = 3) 51 ± 1 87 ± 0.5 

Abbreviation: ND, not done.

F3-150

Percentage of lymphocytes undergoing apoptosis after exposure to anti-CD3 (64.1) or anti-Fas (CH11) MoAb.

F3-151

All patients have Fas mutations, except patient no. 14.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal